Activators of TTC9 include a variety of chemical agents that primarily exert their influence by modulating the cAMP signaling pathway, which is a pivotal cascade in cellular communication impacting numerous physiological functions. Some agents directly stimulate the enzymes or receptors that lead to increased cAMP levels within cells, thus triggering a signaling sequence that can enhance the function of TTC9. This amplification is linked to TTC9's responsiveness within such cAMP-dependent pathways, where it reacts to the heightened levels of this secondary messenger. Other substances work to raise cAMP levels by preventing its breakdown, ensuring prolonged signaling and consequently sustained activation of TTC9. Additionally, stable analogs of cAMP, which are designed to resist enzymatic degradation, act as potent activators of the cAMP signaling pathway, providing continuous stimulation for TTC9's role.
Further, certain molecules employ receptor-mediated mechanisms to boost cAMP production, introducing an additional avenue for regulation of TTC9 activity via these receptor pathways. Agents that activate stress-activated protein kinases similarly play a role in the modulation of TTC9, albeit indirectly, by impacting kinase pathways that TTC9 may be part of during cellular stress responses. Specific inhibitors that target different isoforms of phosphodiesterases adjust the balance of cAMP and cGMP within the cell, subtly influencing the signaling environment for TTC9. Hormonal signals also trigger increases in cAMP through their interaction with G protein-coupled receptors, leading to enhanced TTC9 activity in a cascade-like fashion within the cell's signaling networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective phosphodiesterase inhibitor, increases intracellular cAMP by preventing its breakdown, potentially increasing TTC9 activity through cAMP-dependent pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Acts on adrenergic receptors, which can lead to increased intracellular cAMP levels and activation of cAMP-dependent pathways, indirectly leading to TTC9 activation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A synthetic catecholamine that activates beta-adrenergic receptors, increasing cAMP and potentially enhancing TTC9 activity through cAMP-mediated signaling. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 binds to its receptors, resulting in increased intracellular cAMP, which may promote TTC9 activity via cAMP-dependent signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective inhibitor of phosphodiesterase 4, leading to increased cAMP levels and possible TTC9 activation through cAMP-mediated mechanisms. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Inhibits protein synthesis and can activate stress-activated protein kinases, potentially impacting TTC9 function as part of cellular stress responses. | ||||||
8-CPT-cAMP | 93882-12-3 | sc-201569 sc-201569A | 20 mg 100 mg | $87.00 $316.00 | 19 | |
A cAMP analog that is resistant to degradation by phosphodiesterases, thus enhancing cAMP-mediated signaling and potentially TTC9 activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
A selective phosphodiesterase 3 inhibitor that increases cAMP levels, which could lead to the activation of TTC9 through cAMP-dependent signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Selectively inhibits phosphodiesterase 5, leading to increased cAMP and cGMP levels, which may indirectly enhance TTC9 activity through these signaling molecules. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cell-permeable cAMP analog that activates cAMP-dependent pathways and could thus indirectly increase TTC9 activity by mimicking the action of cAMP. | ||||||